Sarcoid-like Pulmonary Lesion in a Female Patient with Multiple Myeloma and Systemic AL Amyloidosis Treated with Daratumumab: A Case of Spontaneous Regression of Lung Tissue Changes upon Drug Withdrawal
ISSN (print) 1997-6933     ISSN (online) 2500-2139
2024-4
PDF_2024-17-4_370-375 (Russian)

Keywords

multiple myeloma
AL amyloidosis
daratumumab
sarcoid-like reaction
spontaneous regression

How to Cite

Rekhtina I.G., Khyshova V.A., Kovrigina A.M., Silaev M.A., Mendeleeva L.P. Sarcoid-like Pulmonary Lesion in a Female Patient with Multiple Myeloma and Systemic AL Amyloidosis Treated with Daratumumab: A Case of Spontaneous Regression of Lung Tissue Changes upon Drug Withdrawal. Clinical Oncohematology. 2024;(4):370–375. doi:10.21320/2500-2139-2024-17-4-370-375.

Keywords

Abstract

Sarcoid-like drug reaction is a granulomatous inflammation having clinical and morphological similarity with sarcoidosis and developing as a rule on chemo/immunotherapy. An important characteristic of the drug-induced sarcoid-like reaction consists in its time relationship with a drug assignment and also with a regression upon its withdrawal. Sarcoid-like reactions are known to occur on therapy with immune checkpoint inhibitors, interferons, tumor necrosis factor-alpha antagonists, antiretroviral drugs, BRAF inhibitors, and rituximab. However, no reports have been published on a sarcoid-like reaction associated with the monoclonal anti-CD38 therapy despite a wide experience in their use for treating plasma cell neoplasms. This paper reports the first case of sarcoid-like reaction characterized by pulmonary lesions with confluent large-nodular areas that developed on daratumumab maintenance therapy in a female patient with multiple myeloma and systemic AL amyloidosis. This case report proves the probability of a sarcoid-like reaction on daratumumab therapy. Further studies are necessary to understand the pathogenesis of similar reversible damage.

PDF_2024-17-4_370-375 (Russian)

References

  1. Paydas S. Sarcoid-like reaction in cases treated by checkpoint inhibitors. Med Oncol. 2021;38(3):29. doi: 10.1007/s12032-021-01477-y.
  2. Danlos FX, Pages C, Baroudjian B, et al. Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest. 2016;149(5):е133–е136. doi: 10.1016/j.chest.2015.10.082.
  3. Mitchell MA, Hogan K, Amjadi K. Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma. Immunotherapy. 2018;10(14):1189–92. doi: 10.2217/imt-2018-0035.
  4. Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185–92. doi: 10.1158/2326-6066.CIR-15-0102.
  5. Miedema J, Nunes H. Drug-induced sarcoidosis-like reactions. Curr Opin Pulm Med. 2021;27(5):439–47. doi: 10.1097/MCP.0000000000000800.
  6. London J, Grados A, Ferme C, et al. Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature. Medicine (Baltimore). 2014;93(21):e121. doi: 10.1097/MD.0000000000000121.
  7. Mrabet S, Dahmene R, Fradi A, et al. Sarcoid-Like reaction in the kidney following rituximab for mantle lymphoma in a 60-year-old man. Am J Mens Health. 2023;17(2):15579883231159343. doi: 10.1177/15579883231159343.
  8. Iannuzzi M, Rybicki B, Teirstein A. Sarcoidosis. New Engl J Med. 2007;357(21):2153–65. doi: 10.1056/NEJMra071714.
  9. Vogel WV, Guislain A, Kvistborg P, et al. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol. 2012;30(2):e7–e10. doi: 10.1200/JCO.2011.37.9693.
  10. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–94. doi: 10.1182/blood-2015-12-687749.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2024 Clinical Oncohematology